Date: 2015-12-21
Type of information: Nomination
Compound:
Company: Kite Pharma (USA - CA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 21, 2015, Kite Pharma announced that it has appointed Shawn Tomasello to the newly created position of Chief Commercial Officer. With over 30 years of experience in the life sciences industry, Ms. Tomasello has led commercial and medical affairs efforts at Pharmacyclics and commercial efforts at Celgene and Genentech. In her new role, Ms. Tomasello will build Kite\'s commercial and medical affairs operations, reporting to Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer, and Cynthia M. Butitta, Chief Operating Officer and Chief Financial Officer. Prior to joining Kite, Ms. Tomasello served as Chief Commercial Officer at Pharmacyclics, Inc., during which time the brand Imbruvica® was awarded the prestigious 2015 Prix Galien Award for Best Pharmaceutical Agent. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology, in which she oversaw over $4 billion in product revenues. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for six brands encompassing 11 indications. Prior to this, she was National Director of Hematology for Rituxan® at Genentech, representing the most significant portion of the company\'s product revenue during her tenure. Earlier in her career, Ms. Tomasello held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. She currently serves on the Boards of Oxford BioTherapeutics and Diplomat Rx. Ms. Tomasello received her BS degree in marketing from the University of Cincinnati and her MBA degree from Murray State University, KY.
Financial terms:
Latest news:
